WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Pope visits Venice to speak to the artists and inmates behind the Biennale's mustDua Lipa and her boyfriend Callum Turner put on a lovedLyon to face Barcelona in the Women's Champions League final after ousting PSGKawhi Leonard ruled out with knee issue as Clippers face Mavs in Game 4Nuggets, Thunder have chances to move into Round 2, and Boston seeks 3Body of climber recovered after 1,000Celtics coach Joe Mazzulla says playoff basketball doesn't change much from regular seasonPip Edwards looks chic in allRizzo hits 300th HR and Judge and Volpe also go deep in Yankees' 15Gladbach, Union Berlin draw 0